OR WAIT null SECS
There are positive indications for future growth.
Revolutionary therapies restructure pharmaceutical manufacturing.
Single-use technologies provide a barrier between operators and drug products, allowing for sterility and personnel safety in manufacturing.
March 15, 2024
ProBioGen and Mapp Biopharmaceutical will use the former’s GlymaxX technology to develop a cell line for an afucosylated antibody that targets Marburg virus infection
March 13, 2024
Under a new agreement, Chime Biologics will manufacture Domain Therapeutics’ antibody cancer immunotherapy candidate, DT-7012.
March 12, 2024
The Italian company’s North American business has seen an increase of 47%.
March 11, 2024
The Alliance will receive the NSF Regional Innovation Engines Development Award and $1 million in funding.
March 02, 2024
Despite a growing number of biosimilar approvals, market uptake remains a challenge.
The authors evaluated the potential of direct filtration for multiple biopharmaceutical candidates. This article is Part 2 of the study.
Proprietary cell lines offer opportunities for achieving high AAV titers.
A tidal wave of questions floats the need for more upstream automation.
March 01, 2024
Given the criticality of fill/finish processes, it is clear that automation is the next technological step.
The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.